Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib, Durvalumab, and Tremelimumab in Recurrent BRCA-Mutated Ovarian Cancer
NCT02953457Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jun 2017
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib, durvalumab and tremelimumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Incidence of Dose-limiting Toxicities at 8 weeks and Progression Free Survival at 3 months. Started Jun 2017; status: completed.
02
Drugs
olaparibdurvalumabtremelimumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02953457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953457.